TITLE

New treatments for genotype I chronic hepatitis C - focus on simeprevir

AUTHOR(S)
Kanda, Tatsuo; Nakamoto, Shingo; Wu, Shuang; Yokosuka, Osamu
PUB. DATE
May 2014
SOURCE
Therapeutics & Clinical Risk Management;2014, Vol. 10, p387
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second -generation HCV NS3/4A protease inhibitors - in combination with peginterferon а-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice. This review summarizes the mechanism of action of simeprevir and the results of clinical trials of simeprevir and peginterferon plus ribavirin for HCV genotype 1 patients. In general, the simeprevir and peginterferon plus ribavirin treatment is highly effective and its adverse events are similar to those of peginterferon plus ribavirin only, the exception being milder, reversible jaundice. In the near future, the development of interferon-free regimens with simeprevir is expected. Careful attention should be paid to new results of clinical trials with simeprevir.
ACCESSION #
96391914

 

Related Articles

  • Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals. Haihong Zhu; Wong-Staal, Flossie; Haekyung Lee; Syder, Andrew; McKelvy, Jeffrey; Schooley, Robert T.; Wyles, David L. // Journal of Infectious Diseases;2/15/2012, Vol. 205 Issue 4, p656 

    ITX 5061 is a scavenger receptor B1 antagonist that has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected humans. We evaluated ITX 5061 in combination with interferon-&alpa;, ribavirin, and HCV protease and polymerase inhibitors in a genotype 2a infectious virus system. ITX...

  • Clinical Benefit of Therapy in Patients with Severe Fibrosis Due to Chronic Hepatitis C Virus (HCV) Infection.  // Clinical Infectious Diseases;3/15/2008, Vol. 46 Issue 6, pvi 

    The article focuses on a medical study which delved into the clinical benefit of therapy in patients with severe fibrosis, due to chronic hepatitis C virus (HCV) infection. The therapy for chronic HCV infection, combined with ribavirin and an Interferon (IFN)-Α preparation, when successful,...

  • TMC435 Effective in the Treatment of HCV Genotype 1 Infection. Butterman, Eric // MD Conference Express;Dec2011, p14 

    The article discusses the effectiveness of TMC435, an oral inhibitor of hepatitis C virus (HCV) in the treatment of HCV genotype 1 infection. Clinical trials are done to determine the efficacy, safety and tolerability of different regimens of TMC435. It also compares the standard treatment to...

  • Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011.  // Biomedical Market Newsletter;5/21/2011, p500 

    The article reports on the announcement of Idera Pharmaceuticals Inc. regarding their data from a Phase 1 Clinical Trial of IMO-2125 in treatment-naïve patients with hepatitis C virus (HCV) presented at the 2011 European Association for the Study of the Liver (EASL). The IMO-2125 in...

  • Hepatitis C Treatment: Trial by Design. Bzeizi, Khalid I. // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p51 

    The author comments on the findings of a study about the treatment outcome of 335 hepatitis C virus (HCV) patients treated with peginterferon α-2a and ribavirin combination therapy in Saudi Arabia. He states that the divergence of the study's findings from the prospective studies published...

  • Peginterferon-α-2a (40 kD) Plus Ribavirin. Keam, Susan J.; Cvetković, Risto S. // Drugs;2008, Vol. 68 Issue 9, p1273 

    Peginterferon-α-2a (40 kD) [PEGASYS®] is a conjugate of recombinant interferon- α-2a and a 40 kD branched polyethylene glycol (PEG) moiety that is highly active against hepatitis C virus (HCV). Ribavirin (COPEGUS®) is a synthetic nucleoside analogue that acts in synergy with the...

  • Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Bartels, Doug J.; Yi Zhou; Zhang, Eileen Z.; Marcial, Michelle; Byrn, Randal A.; Pfeiffer, Thomas; Tigges, Ann M.; Adiwijaya, Bambang S.; Chao Lin; Kwong, Ann D.; Kieffer, Tara L. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p800 

    Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response. Methods....

  • Is it now the time to update treatment protocols for lymphomas with new anti-virus systems? Luppi, M.; Barozzi, P.; Potenza, L.; Riva, G.; Morselli, M.; Torelli, G. // Leukemia (08876924);Oct2004, Vol. 18 Issue 10, p1572 

    Focuses on the result of the application of antiviral therapy with interferon alpha and ribavirin in hepatitis C virus (HCV)-associated marginal zone lymphomas. Efficacy of the treatment; Underlying mechanism of action; Safety profile in terms of general adverse events.

  • Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio // New England Journal of Medicine;1/19/2012, Vol. 366 Issue 3, p216 

    Background: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. Methods: This open-label, phase 2a study included an...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics